Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.44 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29779122 | 1.00 | L3MBTL1 (0.44) | L3MBTL1PDGFRBPDGFRAALDH1A1SMN1; SMN2 | |
| SCHEMBL31026204 | 0.86 | L3MBTL1 (0.44) | L3MBTL1PDGFRBPDGFRAALDH1A1SMN1; SMN2 | |
| SCHEMBL17330449 | 0.86 | L3MBTL1 (0.44) | L3MBTL1PDGFRBPDGFRAALDH1A1SMN1; SMN2 | |
| SCHEMBL17330385 | 0.85 | L3MBTL1 (0.41) | L3MBTL1ALDH1A1SMN1; SMN2HTTSTAT3 | |
| SCHEMBL29779070 | 0.85 | L3MBTL1 (0.48) | L3MBTL1ALDH1A1SMN1; SMN2HTTSTAT3 | |
| SCHEMBL15814340 | 0.85 | L3MBTL1 (0.48) | L3MBTL1ALDH1A1SMN1; SMN2HTTSTAT3 | |
| SCHEMBL17372849 | 0.85 | L3MBTL1 (0.48) | L3MBTL1ALDH1A1SMN1; SMN2HTTSTAT3 | |
| SCHEMBL15815024 | 0.81 | TSHR (0.45) | L3MBTL1ALDH1A1SMN1; SMN2HTTSTAT3 | |
| SCHEMBL30666043 | 0.80 | L3MBTL1 (0.43) | L3MBTL1ALDH1A1SMN1; SMN2HTTSTAT3 | |
| SCHEMBL26688355 | 0.80 | L3MBTL1 (0.43) | L3MBTL1ALDH1A1SMN1; SMN2HTTSTAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479846-B2 | EZH2 inhibitor and use thereof | PHARMABLOCK SCIENCES (NANJING), INC. (CN) | 2025-11-25 | — | — | US | disclosed |
| US-12344618-B2 | Heterotricyclic derivative compound and use of same | HANMI PHARMACEUTICAL CO., LTD. (KR) | 2025-07-01 | — | — | US | disclosed |
| CN-113423710-B | Novel heterocyclic tricyclic derivative compounds and use thereof | 韩美药品株式会社 | 2024-06-14 | — | — | CN | disclosed |
| CN-116457348-A | Novel EZH2 inhibitors and uses thereof | 南京药石科技股份有限公司 | 2023-07-18 | — | — | CN | disclosed |
| CN-116194108-A | Novel dioxoisoquinolinone derivatives and use thereof | 韩美药品株式会社 | 2023-05-30 | — | — | CN | disclosed |
| CN-111909157-B | EZH2 inhibitors and uses thereof | 南京药石科技股份有限公司 | 2023-02-03 | — | — | CN | disclosed |
| US-20220281872-A1 | EZH2 INHIBITOR AND USE THEREOF | PHARMABLOCK SCIENCES (NANJING) , INC. (CN) | 2022-09-08 | — | — | US | disclosed |
| US-20220135582-A1 | NOVEL HETEROTRICYCLIC DERIVATIVE COMPOUND AND USE OF SAME | HANMI PHARMACEUTICAL CO., LTD. (KR) | 2022-05-05 | — | — | US | disclosed |
| EP-3929199-A1 | NOVEL HETEROTRICYCLIC DERIVATIVE COMPOUND AND USE OF SAME | Hanmi Pharmaceutical Co., Ltd. (KR) | 2021-12-29 | — | — | EP | disclosed |
| CN-113423710-A | Novel heterocyclic tricyclic derivative compound and use thereof | 韩美药品株式会社 | 2021-09-21 | — | — | CN | disclosed |
| US-20170298048-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | PFIZER INC. (US) | 2017-10-19 | — | — | US | disclosed |
| EP-3157915-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | Pfizer Inc. (US) | 2017-04-26 | — | — | EP | disclosed |
| US-20160376254-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | PFIZER INC. (US) | 2016-12-29 | — | — | US | disclosed |
| US-20160376254-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | PFIZER INC. (US) | 2016-12-29 | — | — | US | disclosed |
| US-9481666-B2 | Substituted dihydroisoquinolinone compounds | PFIZER INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-9481666-B2 | Substituted dihydroisoquinolinone compounds | PFIZER INC. (US) | 2016-11-01 | — | — | US | disclosed |
| WO-2015193768-A1 | ARYL FUSED LACTAMS AS EZH2 MODULATORS | PFIZER INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015193765-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | PFIZER INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| US-20150361067-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | PFIZER INC. (US) | 2015-12-17 | — | — | US | disclosed |
| US-20150361067-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | PFIZER INC. (US) | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12479846-B2 | EZH2 inhibitor and use thereof | EZH2, BMI1, EZH1 | L3MBTL1 784/4885PDGFRB 3981/4885PDGFRA 4006/4885 |
| US-20220135582-A1 | NOVEL HETEROTRICYCLIC DERIVATIVE COMPOUND AND USE OF SAME | EZH2, EZH1, BMI1 | L3MBTL1 3239/4885PDGFRB 2560/4885PDGFRA 2655/4885 |
| US-20160376254-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, KRAS, TP53 | L3MBTL1 733/4885PDGFRB 1551/4885PDGFRA 1304/4885 |
| US-20170298048-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, KRAS, TP53 | L3MBTL1 733/4885PDGFRB 1551/4885PDGFRA 1304/4885 |
| US-12344618-B2 | Heterotricyclic derivative compound and use of same | EZH2, EZH1, BMI1 | L3MBTL1 2841/4885PDGFRB 2749/4885PDGFRA 2772/4885 |
| US-20220281872-A1 | EZH2 INHIBITOR AND USE THEREOF | EZH2, BMI1, EZH1 | L3MBTL1 784/4885PDGFRB 3981/4885PDGFRA 4006/4885 |
| US-20150361067-A1 | SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, KRAS, TP53 | L3MBTL1 733/4885PDGFRB 1551/4885PDGFRA 1304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.